de en

Reagents and instruments for immunology, cell biology and molecular biology.

Trichostatin A [58880-19-6]

Print

Cat# HY-15144-5mg

Size : 5mg

Contact local distributor :

Phone : +1 850 650 7790

Brand : MedChemExpress

Request more information

Contact local distributor :

Phone : +1 850 650 7790

Description

Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC^[1].

IC₅₀ & Target^[1]

HDAC

1.8 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.22 μM Compound: TSA	Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	0.25 μM Compound: TSA	Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A2780	IC₅₀	0.29 μM Compound: TSA	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	0.43 μM Compound: TSA	Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A-431	IC₅₀	0.18 μM Compound: TSA	Antiproliferative activity against human A431 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A431 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
A549	IC₅₀	0.05 μM Compound: Trichostatin A	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
A549	IC₅₀	0.05 μM Compound: TSA	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
A549	IC₅₀	0.05 μM Compound: TSA	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
A549	IC₅₀	0.08 μM Compound: TSA (1)	Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay	[PMID: 14667227]
A549	IC₅₀	0.16 μM Compound: TSA	Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
A549	IC₅₀	80 nM Compound: TSA	Antiproliferative activity against human A549 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human A549 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
A549	GI₅₀	80 nM Compound: TSA	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 30004697]
BE(2)-C	IC₅₀	0.05 μM Compound: 1, TSA, trichostatin A	Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay	[PMID: 22932316]
Bel-7402	IC₅₀	0.1 μM Compound: TSA	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
BGC-823	IC₅₀	0.07 μM Compound: TSA	Antiproliferative activity against human BGC823 cells after 72 hrs by CCK8 assay Antiproliferative activity against human BGC823 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
BGC-823	IC₅₀	0.08 μM Compound: Trichostatin A	Cytotoxicity against human BGC823 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human BGC823 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
BGC-823	IC₅₀	0.08 μM Compound: TSA	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
BT-474	IC₅₀	33.3 nM Compound: 8; TSA	Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition by SRB assay	[PMID: 34826681]
BXPC-3	GI₅₀	100 nM Compound: TSA	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTS assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTS assay	[PMID: 30004697]
DMS-53	IC₅₀	25 nM Compound: Trichostatin A	Cytostatic activity against human DMS53 cells assessed as inhibition of cell proliferation after 2 days by MTT assay Cytostatic activity against human DMS53 cells assessed as inhibition of cell proliferation after 2 days by MTT assay	[PMID: 21504214]
DU-145	IC₅₀	0.06 μM Compound: TSA	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
DU-145	IC₅₀	0.2 μM Compound: TSA	Inhibitory concentration required to reduce DU145 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce DU145 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
HCT-116	IC₅₀	< 0.05 μM Compound: TSA	Inhibitory concentration required to reduce HCT 116 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce HCT 116 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
HCT-116	IC₅₀	0.013 μM Compound: 1	Concentration required to inhibit the HCT116 cell growth by 50%. Concentration required to inhibit the HCT116 cell growth by 50%.	[PMID: 11831887]
HCT-116	IC₅₀	0.043 μM Compound: 1, TSA	Growth inhibition of human HCT116 cells after 48 hrs by SRB assay Growth inhibition of human HCT116 cells after 48 hrs by SRB assay	[PMID: 21073160]
HCT-116	IC₅₀	0.8 μM Compound: TSA	Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay	[PMID: 20452226]
HCT-116	EC₅₀	1 μM Compound: 1 (trichostatin A)	In vitro antiproliferative activity against human colon cancer HCT 116 cells determined by MMT assay In vitro antiproliferative activity against human colon cancer HCT 116 cells determined by MMT assay	[PMID: 11597413]
HCT-116	GI₅₀	35 nM Compound: TSA	Antiproliferative activity against human HCT-116 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HCT-116 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
HCT-116	GI₅₀	35 nM Compound: TSA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 30004697]
HEK293	IC₅₀	0.16 μM Compound: 5	Cytotoxicity against human HEK293 cells after 96 hrs by MTT assay Cytotoxicity against human HEK293 cells after 96 hrs by MTT assay	[PMID: 25556102]
HeLa	IC₅₀	0.0011 μM Compound: TSA	Inhibition of HDAC2 in human HeLa cell nuclear extracts in presence of dithiothreitol by HDAC fluorescent assay Inhibition of HDAC2 in human HeLa cell nuclear extracts in presence of dithiothreitol by HDAC fluorescent assay	[PMID: 22465091]
HeLa	EC₅₀	0.0052 μM Compound: TSA	Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA	[PMID: 26611919]
HeLa	IC₅₀	0.0075 μM Compound: Trichostatin A	Inhibition of HDAC in human HeLa cell extract after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell extract after 15 mins by fluorescence assay	[PMID: 25455492]
HeLa	IC₅₀	0.02 μM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extract assessed as inhibition of histone H4 deacetylation after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract assessed as inhibition of histone H4 deacetylation after 15 mins by fluorescence assay	[PMID: 20381359]
HeLa	IC₅₀	0.09 μM Compound: TSA	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 27427973]
HeLa	IC₅₀	0.1 μM Compound: Trichostatin A	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
HeLa	IC₅₀	0.11 μM Compound: TSA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HeLa	IC₅₀	0.3 μM Compound: Trichostatin A	Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay	[PMID: 19457659]
HeLa	IC₅₀	0.85 μM Compound: 5	Cytotoxicity against human HeLa cells after 96 hrs by MTT assay Cytotoxicity against human HeLa cells after 96 hrs by MTT assay	[PMID: 25556102]
HeLa	IC₅₀	1.42 nM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay	[PMID: 26588603]
HeLa	IC₅₀	12 nM Compound: TSA	Inhibition of HDAC isolated from human HeLa cells by fluorimetric assay Inhibition of HDAC isolated from human HeLa cells by fluorimetric assay	10.1039/C4MD00211C
HeLa	IC₅₀	28.9 nM Compound: TSA	Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay	[PMID: 20167479]
HeLa	IC₅₀	3 nM Compound: TSA	Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay	[PMID: 21621883]
HeLa	IC₅₀	3 nM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorimetric assay Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorimetric assay	[PMID: 19705846]
HeLa	IC₅₀	3 nM Compound: TSA	Inhibition of HDAC in human HeLa cell cytosolic extract after 30 mins by fluorimetric assay Inhibition of HDAC in human HeLa cell cytosolic extract after 30 mins by fluorimetric assay	[PMID: 19705846]
HeLa	IC₅₀	39 nM Compound: TSA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30245394]
HeLa	IC₅₀	41 nM Compound: TSA	Inhibition of Histone deacetylase in HeLa cell nuclear extracts by fluorescence-based assay Inhibition of Histone deacetylase in HeLa cell nuclear extracts by fluorescence-based assay	[PMID: 17419603]
HeLa	IC₅₀	5 nM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay	[PMID: 19914074]
HeLa	IC₅₀	5 nM Compound: TSA	Inhibition of human HDAC in HeLa cells by flour de lys assay Inhibition of human HDAC in HeLa cells by flour de lys assay	[PMID: 18397827]
HepG2	EC₅₀	0.38 μM Compound: 5	Up-regulation of transcriptional activity of human CLA-1 promoter region -1055 to -62bp transfected in HepG2 cells by luciferase reporter gene assay Up-regulation of transcriptional activity of human CLA-1 promoter region -1055 to -62bp transfected in HepG2 cells by luciferase reporter gene assay	[PMID: 25556102]
HepG2	IC₅₀	0.96 μM Compound: 5	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 25556102]
HL-60	IC₅₀	0.03 μM Compound: Trichostatin A	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
HL-60	IC₅₀	0.08 μM Compound: TSA	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HL-60	GI₅₀	0.59 μM Compound: TRICHOSTATIN A	Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay	[PMID: 29454918]
HMEC	IC₅₀	1.6 μM Compound: TSA	Inhibitory concentration required to reduce normal human epithelial cell line (HMEC), growth by 50% in MTT assay Inhibitory concentration required to reduce normal human epithelial cell line (HMEC), growth by 50% in MTT assay	[PMID: 12061890]
HT-1080	IC₅₀	0.08 μM Compound: TSA	Antiproliferative activity against human HT1080 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HT1080 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
HT-29	IC₅₀	3.8 nM Compound: TSA	Antiproliferative activity against human HT-29 cells in presence of isoCA-4 after 72 hrs by MTS assay relative to control Antiproliferative activity against human HT-29 cells in presence of isoCA-4 after 72 hrs by MTS assay relative to control	[PMID: 30004697]
HT-29	GI₅₀	34.1 nM Compound: TSA	Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 30004697]
HT-29	IC₅₀	55 nM Compound: TSA	Antiproliferative activity against human HT-29 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HT-29 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
Huh-7	IC₅₀	0.06 μM Compound: TSA	Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
Huh-7	IC₅₀	0.09 μM Compound: Trichostatin A	Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
Huh-7	IC₅₀	0.1 μM Compound: TSA	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HUVEC	IC₅₀	20 nM Compound: TSA, trichostatin A	Inhibition of IL-1-beta-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of IL1-beta challenge by one stage clotting assay Inhibition of IL-1-beta-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of IL1-beta challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	20 nM Compound: TSA, trichostatin A	Inhibition of HOSCN-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of HOSCN challenge by one stage clotting assay Inhibition of HOSCN-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of HOSCN challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	20 nM Compound: TSA, trichostatin A	Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	30 nM Compound: TSA, trichostatin A	Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay	[PMID: 17675290]
K562	IC₅₀	0.12 μM Compound: TSA	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
K562	IC₅₀	0.16 μM Compound: Trichostatin A	Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
K562	IC₅₀	0.41 μM Compound: TSA	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
K562	IC₅₀	260 nM Compound: TSA	Antiproliferative activity against human K562 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human K562 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
K562	GI₅₀	262 nM Compound: TSA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 30004697]
K562	IC₅₀	560 nM Compound: TSA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 30245394]
K562	IC₅₀	90 nM Compound: TSA	Antiproliferative activity against imatinib-resistant human K562 cells over expressing MDR1 after 72 hrs by CellTiter Glo assay Antiproliferative activity against imatinib-resistant human K562 cells over expressing MDR1 after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
K-562R	GI₅₀	88 nM Compound: TSA	Antiproliferative activity against human K562R cells after 72 hrs by MTS assay Antiproliferative activity against human K562R cells after 72 hrs by MTS assay	[PMID: 30004697]
L02	IC₅₀	0.21 μM Compound: 5	Cytotoxicity against human LO2 cells after 96 hrs by MTT assay Cytotoxicity against human LO2 cells after 96 hrs by MTT assay	[PMID: 25556102]
MCF7	IC₅₀	0.06 μM Compound: Trichostatin A	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
MCF7	IC₅₀	0.06 μM Compound: TSA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
MCF7	IC₅₀	0.07 μM Compound: TSA	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
MCF7	IC₅₀	0.1 μM Compound: TSA	Inhibitory concentration required to reduce MCF-7 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce MCF-7 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
MCF7	IC₅₀	1.7 μM Compound: TSA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22465091]
MCF7	IC₅₀	141 nM Compound: TSA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30245394]
MCF7	IC₅₀	27.7 nM Compound: 8; TSA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay	[PMID: 34826681]
MCF7	GI₅₀	45 nM Compound: TSA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 30004697]
MCF7	IC₅₀	54 nM Compound: TSA	Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
MDA-MB-231	IC₅₀	0.09 μM Compound: TSA	Inhibitory concentration required to reduce MDAmb 231 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce MDAmb 231 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
MDA-MB-231	IC₅₀	91 nM Compound: TSA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
MDA-MB-435	GI₅₀	1.78 μM Compound: TRICHOSTATIN A	Antiproliferative activity against human MDA-MB-435 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-435 cells after 24 hrs by MTT assay	[PMID: 29454918]
MDCK	IC₅₀	0.008 μM Compound: Trichostatin A	Antiviral activity against Influenza A virus A/Hong Kong/8/68 H3N2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by CCK8 assay Antiviral activity against Influenza A virus A/Hong Kong/8/68 H3N2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by CCK8 assay	10.1039/C3MD00371J
MIA PaCa-2	IC₅₀	200 nM Compound: TSA	Antiproliferative activity against human MIA PaCa-2 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MIA PaCa-2 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
MIA PaCa-2	GI₅₀	200 nM Compound: TSA	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTS assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTS assay	[PMID: 30004697]
MOLT-4	IC₅₀	0.02 μM Compound: TSA	Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
MOLT-4	IC₅₀	0.03 μM Compound: Trichostatin A	Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
MOLT-4	IC₅₀	0.03 μM Compound: TSA	Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
NCI-H1975	IC₅₀	0.09 μM Compound: Trichostatin A	Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
NCI-H1975	IC₅₀	0.21 μM Compound: TSA	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
NCI-H446	IC₅₀	0.08 μM Compound: TSA	Inhibitory concentration required to reduce H446 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce H446 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
NCI-H460	IC₅₀	0.1 μM Compound: 1, TSA	Growth inhibition of human H460 cells after 48 hrs by SRB assay Growth inhibition of human H460 cells after 48 hrs by SRB assay	[PMID: 21073160]
NCI-H661	IC₅₀	0.085 μM Compound: 7, TSA	Antiproliferative activity against H661 cells after 48 hrs by XTT assay Antiproliferative activity against H661 cells after 48 hrs by XTT assay	[PMID: 17624773]
NCI-H661	IC₅₀	0.085 μM Compound: 1 (TSA)	Antiproliferative activity against H661 cells after 48 hrs Antiproliferative activity against H661 cells after 48 hrs	[PMID: 17897824]
NCI-H661	IC₅₀	0.1 μM Compound: 1, TSA	Antiproliferative activity against human NCI-H661 cells after 48 hrs by XTT assay Antiproliferative activity against human NCI-H661 cells after 48 hrs by XTT assay	[PMID: 19385600]
NCI-N87	IC₅₀	0.06 μM Compound: TSA	Antiproliferative activity against human NCI-N87 cells after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-N87 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
NCI-N87	IC₅₀	58 nM Compound: TSA	Antiproliferative activity against human NCI-N87 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human NCI-N87 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
NIH3T3	IC₅₀	0.006 μM Compound: Trichostatin A	Inhibition of HDAC1 in human NIH3T3 cells by radiometric histone deacetylation assay Inhibition of HDAC1 in human NIH3T3 cells by radiometric histone deacetylation assay	[PMID: 19457659]
PANC-1	IC₅₀	0.1 μM Compound: TSA	Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
PC-3	GI₅₀	387 nM Compound: TSA	Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay	[PMID: 30004697]
Sf21	IC₅₀	0.032 μM Compound: TSA	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay	[PMID: 30448419]
Sf21	IC₅₀	1.58 x 10^-2 μM Compound: Trichostatin A	Inhibition of recombinant full length human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorimetric assay Inhibition of recombinant full length human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorimetric assay	[PMID: 31838329]
Sf21	IC₅₀	17.9 nM Compound: Trichostatin A	Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	[PMID: 31924504]
Sf21	IC₅₀	25 nM Compound: TSA	Inhibition of recombinant human GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay Inhibition of recombinant human GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay	[PMID: 32212730]
Sf21	IC₅₀	3.95 x 10^-2 μM Compound: Trichostatin A	Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorimetry assay Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorimetry assay	[PMID: 31838329]
Sf21	IC₅₀	6.574 nM Compound: TSA	Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	[PMID: 27060764]
Sf21	IC₅₀	9 nM Compound: TSA	Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 insect cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by flu Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 insect cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by flu	[PMID: 32212730]
Sf9	IC₅₀	> 1 μM Compound: TSA	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	> 1 μM Compound: TSA	Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.000681 μM Compound: TSA	Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.00161 μM Compound: TSA	Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.002 μM Compound: TSA	Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by s Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by s	[PMID: 31414801]
Sf9	IC₅₀	0.00274 μM Compound: TSA	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.009 μM Compound: TSA	Inhibition of recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mi Inhibition of recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mi	[PMID: 31414801]
Sf9	IC₅₀	0.482 μM Compound: TSA	Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.776 μM Compound: TSA	Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.9 nM Compound: TSA	Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	1.2 nM Compound: TSA	Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate	[PMID: 23009203]
Sf9	IC₅₀	1.716 nM Compound: TSA	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 27060764]
Sf9	IC₅₀	129 nM Compound: TSA	Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	15.7 nM Compound: Trichostatin A	Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
Sf9	IC₅₀	17.3 nM Compound: TSA	Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	5 nM Compound: TSA	Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate	[PMID: 23009203]
Sf9	IC₅₀	5 nM Compound: TSA	Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	5 nM Compound: TSA	Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	9 nM Compound: TSA	Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	960 nM Compound: 1, TSA	Inhibition of N terminal hexahistidine-tagged human HDAC8 expressed in Sf9 cells after 1 hr by fluorescence assay Inhibition of N terminal hexahistidine-tagged human HDAC8 expressed in Sf9 cells after 1 hr by fluorescence assay	[PMID: 21723733]
SGC-7901	IC₅₀	0.03 μM Compound: TSA	Antiproliferative activity against human SGC7901 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SGC7901 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
SH-SY5Y	IC₅₀	18.8 nM Compound: Trichostatin A	Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SH-SY5Y	IC₅₀	7.8 nM Compound: Trichostatin A	Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SH-SY5Y	IC₅₀	9.1 nM Compound: Trichostatin A	Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SK-BR-3	IC₅₀	0.05 μM Compound: TSA	Antiproliferative activity against human SK-BR-3 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SK-BR-3 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
SK-OV-3	IC₅₀	100 nM Compound: TSA	Antiproliferative activity against human SK-OV-3 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SK-OV-3 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
SW48	IC₅₀	0.1 μM Compound: TSA	Inhibitory concentration required to reduce SW48 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce SW48 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
T-24	IC₅₀	0.15 μM Compound: TSA	Inhibitory concentration required to reduce T24 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce T24 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
T47D	IC₅₀	26.4 nM Compound: 8; TSA	Antiproliferative activity against human T47D cells assessed as cell growth inhibition by burton method Antiproliferative activity against human T47D cells assessed as cell growth inhibition by burton method	[PMID: 34826681]
U-251	IC₅₀	611.2 nM Compound: 2	Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	[PMID: 17643112]
U2OS	IC₅₀	14.93 μM Compound: 5	Cytotoxicity against human U2OS cells after 96 hrs by MTT assay Cytotoxicity against human U2OS cells after 96 hrs by MTT assay	[PMID: 25556102]
U-87MG ATCC	GI₅₀	1038 nM Compound: TSA	Antiproliferative activity against human U87 cells after 72 hrs by MTS assay Antiproliferative activity against human U87 cells after 72 hrs by MTS assay	[PMID: 30004697]
U-937	IC₅₀	0.04 μM Compound: TSA	Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
U-937	IC₅₀	0.05 μM Compound: Trichostatin A	Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
U-937	IC₅₀	0.1 μM Compound: TSA	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
Vero	IC₅₀	0.6 μM Compound: Trichostatin A	Antiviral activity against EV71 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 to 96 hrs by CCK8 assay Antiviral activity against EV71 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 to 96 hrs by CCK8 assay	10.1039/C3MD00371J
Vero	IC₅₀	41.2 ng/mL Compound: TSA	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	49.5 ng/mL Compound: TSA	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	95 ng/mL Compound: TSA	Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay	[PMID: 19914074]

In Vitro

Trichostatin A is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC. Trichostatin A (TSA) inhibits proliferation of eight breast carcinoma cell lines with mean±SD IC₅₀ of 124.4±120.4 nM (range, 26.4-308.1 nM). HDAC inhibitory activity of Trichostatin A is similar in all cell lines with mean IC₅₀ of 2.4±0.5 nM (range, 1.5-2.9 nM)^[1]. Trichostatin A (330 nM) increases Gαs protein expression in human myometrial cells, but does not increase Gαs mRNA levels^[2]. Trichostatin A (20-75 nM) induces minimal cytotoxicity to adipose-derived stem cells (ADSCs), and enhances the osteogenic differentiation capacity of ADSCs^[3]. In addition, Trichostatin A (0, 10, 100, 500 nM) dose-dependently decreases HDAC class I/II activity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (165.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Methanol : 2 mg/mL (6.61 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3072 mL	16.5360 mL	33.0721 mL
5 mM	0.6614 mL	3.3072 mL	6.6144 mL
10 mM	0.3307 mL	1.6536 mL	3.3072 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.27 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 2.5 mg/mL (8.27 mM); Suspended solution; Need ultrasonic
Protocol 4

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

Purity & Documentation

Purity: 99.91%

Data Sheet (277 KB) SDS (393 KB)

COA (243 KB) HNMR (263 KB) LCMS (265 KB) OR (170 KB) Elemental Analysis Report (101 KB)

Handling Instructions (2659 KB)

References

[1]. Vigushin DM et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001 Apr;7(4):971-6. [Content Brief]

[2]. Karolczak-Bayatti M, et al. Expression of the GTP-Binding Protein Gαs in Human Myometrial Cells is Regulated by Ubiquitination and Protein Degradation: Involvement of Proteasomal Inhibition by Trichostatin A.,Reprod Sci. 2012 Aug 8. [Content Brief]

[3]. Hu X, et al. Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signaling-dependent manner.,Stem Cells Dev. 2012 Aug 8. [Content Brief]

[4]. Azechi T, et al. Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase. J Atheroscler Thromb. 2013;20(6):538-47. [Content Brief]

You might also be interested by the following products:

Cat#

Description

Cond.

Price Bef. VAT

A1906-10mg

Decitabine (NSC127716, 5AZA-CdR) [2353-33-5]

10mg

A8171-10mg

Entinostat (MS-275,SNDX-275) [209783-80-2]

10mg

Trichostatin A [58880-19-6]

Cat# HY-15144-5mg

Contact local distributor :

Brand : MedChemExpress

Contact local distributor :

Trichostatin A Related Antibodies

You might also be interested by the following products: